Claro Advisors LLC Has $1.33 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Claro Advisors LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 118.6% in the first quarter, Holdings Channel reports. The institutional investor owned 4,691 shares of the medical research company’s stock after buying an additional 2,545 shares during the period. Claro Advisors LLC’s holdings in Amgen were worth $1,334,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. BOK Financial Private Wealth Inc. acquired a new position in shares of Amgen in the 4th quarter valued at approximately $29,000. United Community Bank bought a new position in Amgen in the fourth quarter valued at approximately $29,000. Planned Solutions Inc. acquired a new position in Amgen during the fourth quarter valued at approximately $30,000. Delos Wealth Advisors LLC lifted its stake in Amgen by 2,500.0% during the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after purchasing an additional 100 shares during the last quarter. Finally, Hartford Financial Management Inc. boosted its holdings in shares of Amgen by 56.9% in the 4th quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 41 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on AMGN. Mizuho boosted their price target on Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a report on Thursday, May 9th. Royal Bank of Canada increased their target price on shares of Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a report on Friday, June 14th. Truist Financial reaffirmed a “buy” rating and set a $320.00 price target on shares of Amgen in a report on Friday, April 12th. UBS Group upped their price objective on shares of Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Finally, TD Cowen cut their target price on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research report on Wednesday, April 17th. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $307.35.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares in the company, valued at approximately $3,094,268.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.69% of the stock is currently owned by corporate insiders.

Amgen Trading Down 0.5 %

Shares of NASDAQ:AMGN traded down $1.44 during trading on Monday, reaching $311.01. The stock had a trading volume of 1,768,651 shares, compared to its average volume of 2,783,121. Amgen Inc. has a 52 week low of $218.44 and a 52 week high of $329.72. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. The firm’s fifty day moving average is $301.56 and its 200 day moving average is $292.30. The stock has a market cap of $166.84 billion, a price-to-earnings ratio of 44.36, a P/E/G ratio of 2.82 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. The business had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.98 earnings per share. As a group, equities analysts forecast that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.